TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06476418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: distraction
Description: Questionnaires and scales will be filled out by the researcher 5 minutes before blood collection. The child will be allowed to play with the liquid moving, timed fountain toy 3 minutes before blood collection. During the process, the child will continue to play with the toy. The scales will be filled again 5 minutes after blood collection.
Study: NCT06201897

Intervention type: DRUG
Group type: OTHER
Intervention: ACTH/Oral Steroids
Description: Injection ACTH or Oral Steroids in children with West Syndrome
Study: NCT05194735

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen specific TCR-T cell drug product
Description: Phase I:~Ascending dose, single Infusion of TCR+ Cells~Phase II:~Single infusion at the RP2D

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen specific TCR-T cell drug product
Description: Phase I:~Ascending dose, single Infusion of TCR+ Cells~Phase II:~Single infusion at the RP2D

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin (IL-2)
Description: To support growth and activation of TCR-T cell drug product
Study: NCT06067360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IFIS sleeve
Description: IFIS sleeve will be inserted to prevent iris prolapse
Study: NCT05926388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-assisted training
Description: Patients will be given training on insulin therapy and management using lecture, question-answer, video and demonstration methods.
Study: NCT05507775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin tablet
Description: Participants will be treated with digoxin tablets for 3 weeks. On the first they, participants will start with a starting dosage of 3x0.25mg with 6 hours between each administration. Thereafter they will continue with a dosage of 1x0.25mg. Participants aged \>70 years or with body weight \<55kg will initiate a starting dosage of 3x0.125mg with 6 hours between each administration. Thereafter they will continue with a dosage of 1x0.125mg.~After one week the blood concentration of digoxin will be measured. According to this blood concentration, the dose of digoxin will be adjusted.
Study: NCT05439486

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric oxygen therapy within hyperbaric oxygen therapy chamber.
Description: ED patients in this group exposed to hyperbaric oxygen 100 % concentration at 2.2 ATM for 90 minutes for 30 consecutive sessions.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: hyperbaric oxygen therapy within hyperbaric oxygen therapy chamber.
Description: ED patients in this group exposed to hyperbaric oxygen 100 % concentration at 2.2 ATM for 90 minutes for 30 consecutive sessions.
Study: NCT06032780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Resistive Training + Aerobic training Group
Description: Eccentric Resistive training includes upper limb (biceps and triceps) and lower limb large muscle training (quadriceps and hamstrings) 2 sets of 12 repetitions (reps) for each group of muscles in lengthened position for eccentric training in approx. 20 minutes (min). Intensity will be based on 1 repetition maximum (1RM) starting from 20% of (1RM) and its intensity in percentage will be progress by 10% after every two weeks. Stair descending training and squatting position and eccentric hamstring curls with weights at ankle for lower limb eccentric training progressive as per tolerance in response to modified Borg scale (with cut off of showing dyspnea of 4 somewhat hard) and Numeric Pain rating scale (with cut off of showing 7 on scale, crossing moderate pain) . (approx. 20 min).~+ Aerobic training as a control will be given to this group as well for approximately 30 minutes per session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training + Aerobic training Group
Description: Resistive training (concentric) includes Upper limb (biceps and triceps) and lower limb large muscle training (quadriceps and hamstrings), 2 sets of 12 reps for each group of muscles in approx. 30 min. Intensity will be based on 1 repetition maximum (1RM) starting from 20% of (1RM) and its intensity in percentage will be progress by 10% after every two weeks. Stair climbing training and quadriceps training + standing hamstring curls with weight at ankle for lower limb concentric training progressive as per tolerance in response to modified Borg scale (with cut off of showing dyspnea of 4 somewhat hard) and Numeric Pain rating scale (with cut off of showing 7 on scale, crossing moderate pain)~+ Aerobic training as a control will be given to this group as well for approximately 30 minutes per session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic training Group
Description: Aerobic training as a control will be given to this group as well for approximately 60 minutes per session. Aerobic training exercise will be completed via a ergometer/stationary cycle; type will be continuous aerobic exercise and intensity of 60% of max HR (or peak VO2) in HF individuals.
Study: NCT05755841

Intervention type: OTHER
Intervention: Outpatient management of preterm prelabor rupture of membranes
Description: Patients who will be managed as outpatients will be discharged after 48 hours of hospitalization with the following management:~* Twice weekly fetal cardiotocography.~* Complete blood count once a week.~* A weekly clinical and ultrasound examination.

Intervention type: OTHER
Intervention: Inpatient management of preterm prelabor rupture of membranes
Description: In the Inpatient Care Policy group, the same protocol as outpatient group will be applied, but the patient will not be discharged until delivery.
Study: NCT05723185

Intervention type: OTHER
Intervention: Outpatient visit
Description: Patients will be seen and treated at the outpatient clinic like in the usual care

Intervention type: OTHER
Intervention: Outpatient visit
Description: Patients will be seen and treated at the outpatient clinic like in the usual care
Study: NCT06379737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-systemic Rehabilitation
Description: Patients in group A underwent a 5-week rehabilitation cycle with two weekly sessions, totaling 10 sessions, in a health resort setting. The patients underwent treatments at two health resort facilities located in the Euganean Basin, Veneto, Italy, equipped with pools of the same depth, size, and water type. Each session was structured into four components:~1. thermal mineral-rich aerosol therapy (10 minutes);~2. dryland motor, respiratory, and proprioceptive rehabilitation in the gym (30 minutes);~3. mineral-rich aquatic aerobic, strengthening, and balance exercises (30 minutes);~4. cognitive enhancement interventions (30 minutes). Inhalation treatments and aquatic exercises utilized thermal mineral-rich water, specifically salsobromoiodic water, naturally springing at approximately 80°C and used in pools at a temperature of around 36°C. The chemical-physical properties of the thermal mineral-rich water employed are reported in Table I.~Patients in group B underwent a 5-week rehabilit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multi-systemic Rehabilitation
Description: Patients in group A underwent a 5-week rehabilitation cycle with two weekly sessions, totaling 10 sessions, in a health resort setting. The patients underwent treatments at two health resort facilities located in the Euganean Basin, Veneto, Italy, equipped with pools of the same depth, size, and water type. Each session was structured into four components:~1. thermal mineral-rich aerosol therapy (10 minutes);~2. dryland motor, respiratory, and proprioceptive rehabilitation in the gym (30 minutes);~3. mineral-rich aquatic aerobic, strengthening, and balance exercises (30 minutes);~4. cognitive enhancement interventions (30 minutes). Inhalation treatments and aquatic exercises utilized thermal mineral-rich water, specifically salsobromoiodic water, naturally springing at approximately 80°C and used in pools at a temperature of around 36°C. The chemical-physical properties of the thermal mineral-rich water employed are reported in Table I.~Patients in group B underwent a 5-week rehabilit
Study: NCT06047652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: e-CPD user testing
Description: nurses who meet the criteria will carry out user testing on the e-CPD application via a mobile device. after accessing the e-CPD system the nurse will fill in the System Usability Scale instrument.
Study: NCT06042400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy
Description: An innovative written exposure therapy intervention that addresses psychosocial needs commonly experienced by patients with late stage cancers.
Study: NCT05598593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine+thiotepa+ fludarabine + busulfan
Description: cytarabine+thiotepa+ fludarabine + busulfan intravenous injection
Study: NCT06292091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Captopril 12.5 Mg
Description: 12.5 mg of captopril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Captopril 12.5 Mg
Description: 12.5 mg of captopril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Captopril 12.5 Mg
Description: 12.5 mg of captopril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate 4 G
Description: 4 g of sodium bicarbonate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torsemide 20 MG
Description: 20 mg of torsemide
Study: NCT04820972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiplatelet Agents
Description: using antiplatelet agents in 3 days after surgery
Study: NCT05764382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T'ai Chi and Qigong Rehabilitation
Description: T'ai chi/Qigong is a multidimensional (mind, body, and spirit integrative) and multimodal (strength, flexibility, balance, posture, and light to moderate aerobic) form of exercise that is safe for persons of all ages and physical abilities. The 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation program proposed to be studied is adapted from the WaQi program, a curriculum developed by Master Yang Yang, PhD. Master Yang developed this course based on his own healing journey from severe back pain following a bike accident in 2014.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care as per primary care physican, physical therapist.
Study: NCT04411420

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain modulation with physical pain treatment
Description: Examples of pain modulation with physical pain treatment include spinal manipulation, massage, or transcutaneous electrical nerve stimulation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone delivered self-management counseling for increasing physical activity
Description: Centrally located physical therapy assistants will provide six weeks of telehealth consults to increase physical activity for the patient

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone delivered behavioral treatment for participants with high risk for continued disability
Description: Patients with a higher risk of developing chronic or persistent back pain will be identified using the nine question risk stratification start back screening tool (SBST) and will receive six additional weeks of physical activity instructions and additional pain modulation treatments as needed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient preference treatment protocol
Description: the pain navigator will work through a shared decision making process with the patient to determine the preferred treatment protocol

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nonpharmacological guideline adherent treatment protocol
Description: the pain navigator will select only nonpharmacological guideline adherent treatment options for the patient

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facilitated referrals to existing VA or non-VA pain management resources
Description: the pain navigator will work with the referring physician to select only existing VA or non-VA pain management resources for the patient.
Study: NCT05217199

Intervention type: OTHER
Intervention: Measurements
Description: Demographic information of infants and parents, prenatal, postnatal and natal risk factors, Magnetic Resonance Images (MRI), General Movements (GMs) evaluations of babies with Prechtl method from NICU will be recorded. Video recordings for General Movements (GMs) analyzes with the Prechtl method will be taken at postterm 12th to 20th weeks. The infants' sensory processing (general, auditory, visual, tactile, movement, oral) will be evaluated with the adjusted Infant Sensory Profile-2 (ISP-2) family scale, which will be filled in by their mothers at the 3rd month. For motor assessments, the postterm corrected 3 month Hammersmith Infant Neurological Examination (HINE) will be used. A pediatric neurologist who was blinded to all testing made the diagnosis of CP in a 2-year-old child based on neuroimaging and clinical tests.
Study: NCT04774731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration
Description: Receiving WBV training three times a week before initiation of dialysis sessions for 12 weeks. Subjects stand on a platform of WBV for 3 minutes in every training session.
Study: NCT05802654

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: The participants enrolled will receive single fraction of ultra-high dose SBRT(30Gy/1F).
Study: NCT05575037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: 8-week trial of dupilumab (an anti-IL-4a) in patients with AERD.
Study: NCT04667377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: BI 456906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: BI 456906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: BI 456906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: BI 456906

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05018247

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Revascularization by Coronary Artery Bypass Graft or Percutaneous Coronary Intervention
Description: Urgent revascularization via CABG or PCI combined with Optimal Medical Treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Revascularization by Coronary Artery Bypass Graft or Percutaneous Coronary Intervention
Description: Urgent revascularization via CABG or PCI combined with Optimal Medical Treatment
Study: NCT05623930

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser acupuncture
Description: In fatty liver diseased patients which their number will be 30 patients, a 3-session/week application of 2-minute laser (for 3 months) on acupoint number 25,40,36 of stomach meridian, acupoints number 3 and 14 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9.12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: wet cupping
Description: in this fatty liver diseased patients which their number will be 30, cupping (with scarification) or wet cupping will be applied at the first day and the day number 14 in the month for three successive months. cupping (with scarification) or wet cupping will be applied on urinary bladder acupoint 17 (on the both sides) and governosal vessels acupoints 12,13,and 14.
Study: NCT06372548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Find You! Cure My Animal Friends
Description: Introduced cognitive evaluation theory combined with masking therapy to develop a gamified product that guides amblyopic children to develop habits for the purpose of rehabilitation training.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DuoBao Vision Training System
Description: This is a visual training app where participants are required to complete several training tasks.
Study: NCT05211336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab 1000 mg IV (intravenous) days 1 and 2 for a maximum of 6 cycles every 21 days (each cycle is 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 100 mg PO (by mouth) daily days 1-7 for a maximum of 6 cycles every 21 days (each cycle is 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 10 or 15 mg PO (by mouth) on days 1-14 for 1 cycle (21 days); followed by Lenalidomide 10 or 15 mg PO daily days 1-14 for a maximum of 6 cycles every 21 days (each cycle is 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax 800 mg PO (by mouth) on days 1-14 for a maximum of 6 cycles every 21 days (each cycle is 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib 560 mg PO (by mouth) daily days 1-14 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
Study: NCT05319184

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release Technique and Kinesiology Taping
Description: Myofascial release is a manual release technique that increases the elasticity and glide between soft tissue layers, reduces this increased muscle activity and pain intensity. Myofascial release is usually characterized by prolonged mechanical forces exerted directly or indirectly on the limited fascial layers with low load. Following the direction of the fascial restraint, the therapist's hands slowly maintain the stretch and allow the fascia to relax on its own.~Kinesio Taping is a non-invasive, painless and less time consuming method with fewer side effects. It is an elastic-cotton adhesive tape that is latex-free and can be used on any joint or muscle. It can stretch significantly (130-140% of its original length), which reduces mechanical movement limitations and mimics skin in thickness and elasticity. It is used in the treatment of LBP to reduce muscle tone and stiffness as a rehabilitative taping technique designed to support the body's natural healing process.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release Technique and Kinesiology Taping
Description: Myofascial release is a manual release technique that increases the elasticity and glide between soft tissue layers, reduces this increased muscle activity and pain intensity. Myofascial release is usually characterized by prolonged mechanical forces exerted directly or indirectly on the limited fascial layers with low load. Following the direction of the fascial restraint, the therapist's hands slowly maintain the stretch and allow the fascia to relax on its own.~Kinesio Taping is a non-invasive, painless and less time consuming method with fewer side effects. It is an elastic-cotton adhesive tape that is latex-free and can be used on any joint or muscle. It can stretch significantly (130-140% of its original length), which reduces mechanical movement limitations and mimics skin in thickness and elasticity. It is used in the treatment of LBP to reduce muscle tone and stiffness as a rehabilitative taping technique designed to support the body's natural healing process.
Study: NCT06073015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Group S received a subanesthetic dose of esketamine 0.2mg/kg (2ml/50 mg) 5 minutes before the procedure began.
Study: NCT05415475

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CEA CAR-T cells
Description: Administration method: intravenous infusion or intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CEA CAR-T cells
Description: Administration method: intravenous infusion or intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
Study: NCT04628338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN-γ (interferon gamma-1b) injection
Description: Dosage form: 100 mcg (2 million International Units) per 0.5 mL solution, administered subcutaneously Dose regimen: three times weekly (Weeks 0-7), once weekly (Weeks 8-12)
Study: NCT06261073

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: blood sample and tissue biopsy
Description: Serum level of Cathepsin L: 3 cm of blood will be taken on EDTA tubes from patients and control subjects and will be analyzed by double antibody sandwich enzyme-linked immune-sorbent assay (ELISA) to assess the level of CTSL in blood samples. Tissue expression of Cathepsin L: 5 mm punch biopsies will be taken under local anesthesia from lesions and from the adjacent normal skin of patients (from the lesional and peri-lesional sites). Also, skin biopsy of normal skin will be taken from healthy volunteers. The specimen of skin will be immediately placed in a formalin saline, and then immune-histochemical evaluation will be done to evaluate the CTSL expression in tissue.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: blood sample and tissue biopsy
Description: Serum level of Cathepsin L: 3 cm of blood will be taken on EDTA tubes from patients and control subjects and will be analyzed by double antibody sandwich enzyme-linked immune-sorbent assay (ELISA) to assess the level of CTSL in blood samples. Tissue expression of Cathepsin L: 5 mm punch biopsies will be taken under local anesthesia from lesions and from the adjacent normal skin of patients (from the lesional and peri-lesional sites). Also, skin biopsy of normal skin will be taken from healthy volunteers. The specimen of skin will be immediately placed in a formalin saline, and then immune-histochemical evaluation will be done to evaluate the CTSL expression in tissue.
Study: NCT05840926

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Streptococcus salivarius K12
Description: Oral 1 billion CFU of Probiotic Streptococcus salivarius K12

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No probiotic supplementation
Description: Children who did not receive any probiotic supplementation
Study: NCT04994197

Intervention type: OTHER
Intervention: Observational study only - no intervention
Description: Observational study only - no intervention

Intervention type: OTHER
Intervention: Observational study only - no intervention
Description: Observational study only - no intervention

Intervention type: OTHER
Intervention: Observational study only - no intervention
Description: Observational study only - no intervention

Intervention type: OTHER
Intervention: Observational study only - no intervention
Description: Observational study only - no intervention
Study: NCT06248164

Intervention type: OTHER
Intervention: No intervention
Description: We will not carry out any type of intervention, just observe the behaviors and health parameters of parents and children.